))
Developing Treatments
Manage episode 312495041 series 3236617
Conteúdo fornecido por David Cunnington and SCN2A Australia. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por David Cunnington and SCN2A Australia ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Taking a treatment from the laboratory in to clinical trials and then to becoming available for use is a complex and expensive process. We talk with Dr Kiran Reddy, President and CEO of Praxis Precision Medicines, about the plans for the RC-222 treatment program with the eventual goal of having a treatment available for SCN2A gain-of-function epilepsies.
Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.
Leave a review and subscribe via Apple Podcasts.
You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app
Links:
- Praxis Precision Medicines
- Antisense oligonucleotide therapy for gain-of-function SCN2A epilepsies
- Natural History Study – podcast on SCN2A natural history study
See omnystudio.com/listener for privacy information.
28 episódios
Compartilhar
